Pancreatic cancer genetic marker may predict outcomes with radiation therapy
Pancreatic cancer is one of the most difficult cancers to treat and is a leading cause of cancer-related deaths. Now, Sidney Kimmel Cancer Center – Jefferson Health and Lankenau Institute for Medical Research scientists find that a gene involved in the immune system called IDO2 plays a significant role in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The discovery may help physicians provide better treatment options for patients.
“The findings could point to a therapeutic target or an important prognostic biomarker,” said George Prendergast, PhD, President and CEO of the Lankenau Institute for Medical Research (LIMR) of Main Line Health … Read more . . .